Advertisement

Elastase Inhibitors in the Lung: Expression and Functional Relationships

  • Jean-Michel Sallenave
  • Kevin Morgan
  • Jack Gauldie
  • Noor Kalsheker
Chapter
Part of the Respiratory Pharmacology and Pharmacotherapy book series (RPP)

Abstract

The acute-phase response (APR) is thought to be the response of the body to initiation and development of inflammation. This is a beneficial response, aimed at limiting damage and restoring normal haemostasis. A well-orchestrated sequence of events starts at the site of injury, leading to the systemic release of biological mediators, principally via the liver. The major hepatic acute-phase reactants are composed of serum amyloid A, C-reac-tive protein (CRP), serum amyloid P component, metal-binding proteins such as haptoglobin and ceruloplasmin and proteinase inhibitors such as α1-proteinase inhibitor (also known as α1-antitrypsin) and α1-antichymo-trypsin [1]. Proteinase inhibitors have been extensively studied, because of their ability to inhibit the deleterious effects of proteases, secreted either by foreign bodies such as bacteria, or by endogenous cells such as tissue macrophages, blood monocytes and polymorphonuclear cells.

Keywords

Human Neutrophil Elastase Elastase Inhibitor Chronic Obstructive Airway Disease Porcine Pancreatic Elastase Anti Proteinase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Mackiewicz I, Kushner I, Baumann H (eds) (1993) Acute phase proteins. Molecular biology, biochemistry, and clinical applications. Boca Raton, FL, CRC PressGoogle Scholar
  2. 2.
    Koy A, Gauldie J (1993) Biological perspectives of cytokine and hormone networks. In: I Mackiewicz, I Kushner, H Baumann (eds): Acute phase proteins. Molecular biology, biochemistry, and clinical applications. Boca Raton, FL, CRC Press, 275–287Google Scholar
  3. 3.
    Baumann H, Gauldie J (1994) The acute phase response. Immunol Today 15: 74–80Google Scholar
  4. 4.
    Xing Z, Achong M, Lei X-F, Cox G, Jordana M, Gauldie J (1997) Enhanced pulmonary inflammatory responses to local endotoxin challenge in interleukin-6-deficient mice. Am J Respir Crit Care Med 155: A500Google Scholar
  5. 5.
    Howard M, Muchamuel T, Andrade S, Menon S (1993) Interleukin-10 protects mice from lethal endotoxemia. J Exp Med 177: 1205–1208PubMedGoogle Scholar
  6. 6.
    Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL (1995) Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory pro-tein-2 and tumor necrosis factor. J Immunol 155: 2222–2229PubMedGoogle Scholar
  7. 7.
    Bode W, Huber R (1992) Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 204: 433–451PubMedGoogle Scholar
  8. 8.
    Twining SS (1994) Regulation of proteolytic activity in tissues. Crit Rev Biochem Mol Biol 29: 315–383PubMedGoogle Scholar
  9. 9.
    Salvesen G, Enghild JJ (1993) Proteinase inhibitors: an overview of their structure and possible function in the acute phase. In: Mackiewicz I, Kushner I, Baumann H (eds): Acute phase proteins. Molecular biology, biochemistry, and clinical applications. Boca Raton, FL, CRC Press, 117–147Google Scholar
  10. 10.
    Booth NA (1994) The natural inhibitors of fibrinololysis. In: A.L, Bloom, DP, Thomas, CD, Forbes, EGD, Tuddenham (eds): Haemostasis and thrombosis. London, Churchill Livingstone, 699–717Google Scholar
  11. 11.
    Fritz H (1988) Human mucus proteinase inhibitors (human MPI). Biol Chem Hoppe Seyler 369: 79–82PubMedGoogle Scholar
  12. 12.
    Molhuizen HOF, Schalkwijk J (1995) Structural, biochemical, and cell biological aspects of the serine proteinase inhibitor SKALP/elafin/ESI. Biol Chem Hoppe Seyler 376: 1–7PubMedGoogle Scholar
  13. 13.
    Sallenave JM, Shulmann J, Crosley J, Jordana M, Gauldie J (1994) Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 11: 733–741PubMedGoogle Scholar
  14. 14.
    Kramps JA, Franken C, Dijkman JH (1984) ELIS A for quantitative measurement of low molecular weight bronchial protease inhibitor in human sputum. Am Rev Respir Dis 129: 959–963PubMedGoogle Scholar
  15. 15.
    Abe T, Kobayashi N, Yoshimura K, Trapnell BC, Kim H, Hubbard RC, Brewer MT, Thompson RC, Crystal RG (1991) Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 87: 2207–2215PubMedGoogle Scholar
  16. 16.
    Nara K, Ito S, Ito T, Suzuki Y, Ghoneim MA, Tachibana S, Hirose S (1994) Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed “cementoin”. J Biochem 115: 441–448PubMedGoogle Scholar
  17. 17.
    Pfundt R, van Ruissen F, van Vlijmen-Willems IMJJ, Akemade HAC, Zeeuwen PLJM, Schalkwijk J (1996) Constitutive and inducible expression of SKALP/elaf in provides anti-elastase defence in human epithelia. J Clin Invest 98: 1389–1399PubMedGoogle Scholar
  18. 18.
    Asano S, Kida K, Koyama T, Wada H, Isawa Y, Hosoda K, Masuda K, Suzuki Y (1995) A morphologic study of lung secretory leukoprotease inhibitor in pneumonia. Am J Respir Crit Care Med 151: 1576–1581PubMedGoogle Scholar
  19. 19.
    Perlmutter DH, May LT, Sehgal PB (1989) Interferon b2/interleukin 6 modulates synthesis of α1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells. J Clin Invest 84: 138–144PubMedGoogle Scholar
  20. 20.
    Molmenti EP, Ziambaras T, Perlmutter DH (1993) Evidence for an acute phase response in human intestinal epithelial cells. J Biol Chem 268: 14116–14124PubMedGoogle Scholar
  21. 21.
    Cichy J, Potempa J, Chawla RK, Travis J (1995) Stimulatory effect of inflammatory cytokines and α1-antichymotrypsin expression in human lung-derived epithelial cells. J Clin Invest 95: 2729–2733PubMedGoogle Scholar
  22. 22.
    Sallenave J-M, Tremblay GM, Gauldie J, Richards CD (1997) Oncostatin M but not inter-leukin-6 or leukaemia inhibiting factor, stimulates expression of α1-proteinase inhibitor in A549 human alveolar epithelial cells. J Interferon Cytokine Res 17: 337–346PubMedGoogle Scholar
  23. 23.
    Fryksmark U, Ohlsson K, Rosengren M, Tegner H (1983) Studies on the interaction between leukocyte elastase, antileukoproteinase and the plasma proteinase inhibitors α1-proteinase inhibitor and a2-macroglobulin. Hoppe-Seyler’s Z Physiol Chem 364: 793–800PubMedGoogle Scholar
  24. 24.
    Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ (1990) Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Nat Acad Sci USA 87: 3753–3757PubMedGoogle Scholar
  25. 25.
    Dabbagh GJ, Laurent GJ, Chambers RC (1997) α1-antitrypsin stimulates proliferation and procollagen production by human lung fibroblasts. Am J Respir Crit Care Med 155: A185Google Scholar
  26. 26.
    Seemuller U, Arnhold M, Fritz H, Wiedenmann K, Machleidt, W, Heinzel R, Appelhans H, Gassen HG, Lottspeich F (1986) The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease). Complete amino acid sequence as revealed by protein and cDNA sequencing and structural homology to whey proteins and red sea turtle proteinase inhibitor. FEBS Lett 199: 43–48PubMedGoogle Scholar
  27. 27.
    Gratter MG, Fendrich G, Huber R, Bode W (1988) The 2.5 À X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine α1-chymotrypsin. EMBO J 7: 345–351Google Scholar
  28. 28.
    Stetler G, Brewer MT, Thompson RC (1986) Isolation and sequence of a human gene encoding a potent inhibitor of leukocyte proteases. Nucleic Acids Res 14: 7883–7886PubMedGoogle Scholar
  29. 29.
    Heinzel R, Appelhans H, Gassen G, Seemuller U, Machleidt W, Fritz H, Steffens G (1986) Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus. Eur J Biochem 160: 61–67PubMedGoogle Scholar
  30. 30.
    Maruyama M, Hay JG, Yoshimura K, Chu CS, Crystal RG (1994) Modulation of secretory leukoprotease inhibitor gene expression in human bronchial epithelial cells by phorbol ester. J Clin Invest 94: 368–375PubMedGoogle Scholar
  31. 31.
    Kikuchi T, Abe T, Satoh K, Narumi K, Sakai T, Abe S, Shindoh S, Matsushima K, Nukiwa T (1997) cis-Acting region associated with lung-cell-specific expression of the secretory leukoprotease inhibitor gene. Am J Respir Cell Mol Biol 17: 361–367PubMedGoogle Scholar
  32. 32.
    Faller B, Mely Y, Gerard D, Bieth JG (1992) Heparin-induced conformational change and activation of mucus proteinase inhibitor. Biochemistry 31: 8285–8290PubMedGoogle Scholar
  33. 33.
    Ying QL, Kemme M, Simon SR (1994) Functions of the N-terminal domain of secretory leukoprotease inhibitor. Biochemistry 33: 5445–5450PubMedGoogle Scholar
  34. 34.
    Mellet P, Ermolieff J, Bieth JG (1995) Mapping the heparin-binding site of mucus proteinase inhibitor. Biochemistry 34: 2645–2652PubMedGoogle Scholar
  35. 35.
    Kramps JA, van Twisk C, Appelhans H, Meckelein B, Nikiforov T, Dijkman JH (1990) Proteinase inhibitory activities of antileukoprotease are represented by its second COOH-ter-minal domain. Biochim Biophys Acta 1038: 178–185PubMedGoogle Scholar
  36. 36.
    Meckelein B, Nikoforov T, Clemen A, Appelhans H (1990) The location of inhibitory specificities in human mucus proteinase inhibitor (MPI): separate expression of the COOH-terminal doamin yields an active inhibitor of three different proteinases. Protein Engineering 3: 215–220PubMedGoogle Scholar
  37. 37.
    Eisenberg SP, Hale KK, Heimdal P, Thompson RC (1990) Location of the protease-inhi-bitory region of secretory leukocyte protease inhibitor. J Biol Chem 265: 7976–7981PubMedGoogle Scholar
  38. 38.
    Masuda KI, Kamimura T, Watanabe K, Suga T, Kanesaki M, Takeuchi A, Imaizumi A, Suzuki Y (1995) Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro. Br J Pharmacol 115: 883–888PubMedGoogle Scholar
  39. 39.
    Ohlsson K, Tegner H (1976) Inhibition of elastase from granulocytes by the low molecular weight bronchial protease inhibitor. Scand J Lab Clin Invest 36: 437–445Google Scholar
  40. 40.
    Fink E, Nettelbeck R, Fritz H (1986) Inhibition of mast cell chymase by eglin C and antileukoprotease (HUSI-I). Biol Chem Hoppe Seyler 367: 567–571PubMedGoogle Scholar
  41. 41.
    Gauthier F, Fryksmark U, Ohlsson K, Bieth JG (1982) Kinetics of the inhibition of leukocyte elastase by the bronchial inhibitor. Biochim Biophys Acta 700: 178–183PubMedGoogle Scholar
  42. 42.
    Boudier C, Bieth JG (1989) Mucus proteinase inhibitor: a fast-acting inhibitor of leukocyte elastase. Biochim Biophys Acta 995: 36–41PubMedGoogle Scholar
  43. 43.
    Boudier C, Bieth JG (1992) The proteinase-mucos proteinase inhibitor binding stoichio-metry. J Biol Chem 267: 4370–4375PubMedGoogle Scholar
  44. 44.
    Zitnik RJ, Zhang J, Kashem MA, Kohno T, Lyons DE, Wright CD, Rosen E, Goldberg I, Hayday AC (1997) The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA. Biochem Biophys Res Commun 232: 687–697PubMedGoogle Scholar
  45. 45.
    Zitnik R, Zhang J, Gao X (1997) Cloning and characterization of the murine secretory leukocyte protease inhibitor (SLPI) gene. Am J Respir Crit Care Med 155: A657Google Scholar
  46. 46.
    Abbinante-Niessen JM, Simpson LG, Leikauf GD (1993) Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 265: L2S6–292Google Scholar
  47. 47.
    Kramps JA, Willems LNA, Franken C, Dijkman JH (1988) Antileukoprotease, its role in the human lung. Biol Chem Hoppe-Seyler 369: 83–87PubMedGoogle Scholar
  48. 48.
    Jacquot J, Spilmont C, Burlet H, Fuchey C, Buisson AC, Tournier JM, Gaillard D, Puchel-le E (1994) Glandular-like morphogenesis and secretory activity of human tracheal gland cells in a three-dimensional collagen gel matrix. J Cell Physiol 161: 407–418PubMedGoogle Scholar
  49. 49.
    Appelhans B, Sachse EG, Nikiforov T, Appelhans H, Ebert W (1987) Secretion of antileukoprotease from a human lung tumor cell line. FEBS Lett 224: 14–18PubMedGoogle Scholar
  50. 50.
    Sallenave JM, Silva A, Marsden ME, Ryle AP (1993) Secretion of mucus proteinase inhibitor and elafin by Clara cell and type II pneumocyte cell lines. Am J Respir Cell Mol Biol 8: 126–133PubMedGoogle Scholar
  51. 51.
    Kramps JA, Franken C, Meijer CJLM, Dijkman JH (1981) Localization of low molecular weight protease inhibitor in serous secretory cells of the respiratory tract. J Histochem Cytochem 29: 712–719PubMedGoogle Scholar
  52. 52.
    Kramps JA, Te Boekhorst AH, Fransen JA, Gensel LA, Dijkman JH (1989) Antileukoprotease is associated with elastin fibers in the extracellular matrix of the human lung. An immunoelectron microscopy study. Am Rev Respir Dis 140: 471–476PubMedGoogle Scholar
  53. 53.
    Jin FY, Nathan C, Radzioch D, Ding A (1997) Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 88: 417–426PubMedGoogle Scholar
  54. 54.
    Sallenave JM, Si-Tahar M, Cox G, Chignard M, Gauldie J (1997) Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils. J Leuk Biol 61: 695–702Google Scholar
  55. 55.
    Bohm B, Aigner T, Kinne R, Burkhardt H (1992) The serine-protease inhibitor of cartilage matrix is not a chondrocytic gene product. Eur J Biochem 207: 773–779PubMedGoogle Scholar
  56. 56.
    Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH (1996) Antibacterial activity of antileukoprotease. Infect Immun 64: 4520–4524PubMedGoogle Scholar
  57. 57.
    Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM (1997) Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, pros-taglandin E2, and matrix metalloproteinases. J Clin Invest 99: 894–900PubMedGoogle Scholar
  58. 58.
    Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science229: 869–871PubMedGoogle Scholar
  59. 59.
    Rudolphus A, Kramps JA, Dijkman JH (1991) Effect of human antileukoprotease on experimental emphysema. Eur Respir J 4: 31–39Google Scholar
  60. 60.
    Rudolphus A, Stolk J, Dijkman JH, Kramps JA (1993) Inhibition of lipopolysaccharide-induced pulmonary emphysema by intratracheally instilled recombinant secretory leukocyte proteinase inhibitor. Am Rev Respir Dis 147: 442–447PubMedGoogle Scholar
  61. 61.
    Mulligan MS, Desrochers PE, Chinnaiyan AM, Gibbs DF, Varani J, Johnson KJ, Weiss SJ (1993). In vivo suppression of immune complex-induced alveolitis by secretory leukopro-teinase inhibitor and tissue inhibitor of metalloproteinases 2. Proc Natl Acad Sci USA 90: 11523–11527PubMedGoogle Scholar
  62. 62.
    Sallenave JM, Donnelly SC, Gauldie J, Haslett C (1997) Secretory leukocyte proteinase inhibitor (SLPI), α1-proteinase inhibitor (Alpha-1 Pi) and elafin levels are augmented in the adult respiratory distress syndrome (ARDS). Am J Respir Crit Care Med 155: A651Google Scholar
  63. 63.
    Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W (1997) Monocyte deactivaton in septic patients: restoration by IFN-gamma treatment. Nature Med 3: 678–681PubMedGoogle Scholar
  64. 64.
    Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL et al. (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 271: 1836–1843PubMedGoogle Scholar
  65. 65.
    Sallenave J-M, Xing Z, Simpson AJ, Graham FL, Gauldie J (1998) Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters. Gene Therapy 5: 352–360PubMedGoogle Scholar
  66. 66.
    Hochstrasser K, Albrecht GJ, Schonberger G, Rasche B, Lempart K (1981) An elastase-specific inhibitor from human bronchial mucus. Isolation and characterization. Hoppe-Seyler’s Z Physiol Chem 362: 1369–1375PubMedGoogle Scholar
  67. 67.
    Kramps JA, Klasen EC (1985) Characterization of a low molecular weight anti-elastase isolated from human bronchial secretion. Exp Lung Res 9: 151–165PubMedGoogle Scholar
  68. 68.
    Wiedow O, Schroder J, Gregory H, Young JA, Christopers E (1990) Elafin: an elastase specific inhibitor of human skin. Purification, characterization, and complete amine acid sequence. J Biol Chem 265: 14791–14795PubMedGoogle Scholar
  69. 69.
    Sallenave JM, Ryle AP (1991) Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor. Biol Chem Hoppe-Seyler 372: 13–21PubMedGoogle Scholar
  70. 70.
    Molhuizen HOF, Alkemade HAC, Zeeuwen PLJM, de Jongh GJ, Wieringa B, Schalkwijk J (1993) SKALP/Elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem 268: 12028–12032PubMedGoogle Scholar
  71. 71.
    Sallenave JM, Silva A (1993) Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. Am J Respir Cell Mol Biol 8: 439–445PubMedGoogle Scholar
  72. 72.
    Tremblay GM, Sallenave JM, Israel-Assayag E, Cormier Y, Gauldie J (1996) Elafin/elas-tase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer’s lung. Am J Respir Crit Care Med 154: 1092–1098PubMedGoogle Scholar
  73. 73.
    Campbell EJ, Campbell MA (1988) Pericellular proteolysis by neutrophils in the presence of proteinase inhibitors: effects of substrate opsonization. J Cell Biol 106: 667–676PubMedGoogle Scholar
  74. 74.
    Rice W, Weiss SJ (1990) Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor. Science 249: 178–181PubMedGoogle Scholar
  75. 75.
    Llewellyn-Jones CG, Lomas DA, Stockley RA (1994) Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation. Thorax 49: 567–572PubMedGoogle Scholar
  76. 76.
    Wiedow O, Ludemann J, Utecht B (1991) Elafin is a potent inhibitor of proteinase 3. Bio-chem Biophys Res Commun 174: 6–10Google Scholar
  77. 77.
    Ying QL, Simon SR (1993) Kinetics of the inhibition of human leukocyte elastase by elafin, a 6 kilodalton elastase-specific inhibitor from human skin. Biochemistry 32: 1866–1874PubMedGoogle Scholar
  78. 78.
    Tsunemi M, Kato H, Nishiuchi Y, Kumagaye S, Sakakibara S (1992) Synthesis and structure-activity relationship of elafin, an elastase-specific inhibitor. Biochem Biophys Res Commun 185: 967–973PubMedGoogle Scholar
  79. 79.
    Henninghausen LG, Sippel AE, Hobbs AA, Rosen JM (1982) Comparative sequence analysis of the mRNAs coding for mouse and rat whey protein. Nucleic Acid Res 10: 3733–3744Google Scholar
  80. 80.
    Araki K, Kuwada M, Ito O, Kuroki J, Tachibana S (1990) Four disulfide bonds allocation of Na7H+-ATPase inhibitor (SPal). Biochem Biophys Res Commun 172: 42–46PubMedGoogle Scholar
  81. 81.
    Tsunemi M, Matsuura Y, Sakakibara S, Katsube Y (1996) Crystal structure of an elastase-specific inhibitor elafin complexed with procine pancreatic elastase determined at 1.9 A resolution. Biochemistry 35: 11570–11576PubMedGoogle Scholar
  82. 82.
    Saheki T, Ito F, Hagiwara H, Saito Y, Kuroki J, Tachibana S, Hirose S (1992) Primary structure of the human elafin precursor preproelafin deduced from the nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegment. Biochem Biophys Res Commun 185: 240–245PubMedGoogle Scholar
  83. 83.
    Zhang M, Zou Z, Maass N, Sager R (1995) Differential expression of elafin in human normal mammary epithelial cells and carcinomas is regulated at the transcriptional level. Cancer Res 55: 2537–2541PubMedGoogle Scholar
  84. 84.
    Lundwall A, Lazure C (1995) A novel gene family encoding proteins with highly differing structure because of a rapidly evolving exon. FEBS Lett 314: 53–56Google Scholar
  85. 85.
    Lundwall A, Ulvsback M (1996) The gene of the protease inhibitor SKALP/Elafin is a member of the Rest gene family. Biochem Biophys Res Commun 221: 323–327PubMedGoogle Scholar
  86. 86.
    Molhuizen HOF, Zeeuwen PLJM, Weghuis DO, Geurts van Kessel A, Schalkwijk J (1994) Assignment of the human gene encoding the epidermal serine proteinase inhibitor SKALP (P13) to chromosome region 20ql2-ql3. Cytogenet Cell Genet 66: 129–131PubMedGoogle Scholar
  87. 87.
    Crystal RG (1989) The α1-antitrypsin gene and its deficiency states. TIG 5: 411–417PubMedGoogle Scholar
  88. 88.
    Laurell C-B, Eriksson S (1963) The electrophoretic arglobulin pattern of serum in α1-antitrypsin deficiency. Scand J Lab Invest 15: 132–140Google Scholar
  89. 89.
    Carrell RW, Jeppsson J-O, Laurrel C-B, Brennan SO, Owen MC, Vaughn L, Boswell DR (1987) Structure and variation of human α1-antitrypsin (Review). Nature (Lond) 298: (5872) 329–334Google Scholar
  90. 90.
    Travis J, Salvesen G (1983) Human plasma proteinase inhibitors. Annn Rev Biochem 52: 655–709Google Scholar
  91. 91.
    Crystal RG (1990) α1-Antitrypsin deficiency, emphysema and liver disease. J Clin Invest 85: 1343–1352PubMedGoogle Scholar
  92. 92.
    Mittman C, Barbela T, Liebermann J (1973) α1-Antitrypsin deficiency as an indicator of susceptibility to pulmonary disease. J Occup Med 15: 33–38PubMedGoogle Scholar
  93. 93.
    Hay JW, Robin ED (1991) Cost-effectiveness of α1-antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health 81: 427–433PubMedGoogle Scholar
  94. 94.
    Cohen BH, Ball WC, Bias WB (1975) A genetic epidemiologic study of chronic obstructive pulmonary disease I: study design and preliminary observation. Johns Hopkins Med J 137: 94–104Google Scholar
  95. 95.
    Brantly M, Nukiwa T, Crystal RG (1988) Molecular basis of α1-antitrypsin deficiency. Am J Med 84: 13–31PubMedGoogle Scholar
  96. 96.
    Yoshida A, Lieberman J, Gaidulis I, Ewing C (1976) Molecular abnormality of human α1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency. Proc Natl Acad Sci USA 73: 1324–1328PubMedGoogle Scholar
  97. 97.
    Owen MC, Carrell RW (1976) α1-Antitrypsin: molecular abnormality of S variant. BMJ 1: 130–131Google Scholar
  98. 98.
    Kalsheker N, Hodgson, Watkins GL, White JP, Morrison HM, Stockley RA (1987) DNA Polymorphism of the α1-antitrypsin gene in chronic lung disease. BMJ 294: 1511–1514PubMedGoogle Scholar
  99. 99.
    Poller W, Meissen C, Olek K (1990) DNA polymorphims of the α1-antitrypsin gene region in patients with chronic obstructive disease. Eur J Clin Invest 20: 1–7PubMedGoogle Scholar
  100. 100.
    Morgan K, Scobie G, Kalsheker N (1993) Point mutation in a 3′ flanking sequence of the α1-antitrypsin gene associated with chronic respiratory disease occurs in a regulatory sequence. Hum Mol Genet 2: 253–257PubMedGoogle Scholar
  101. 101.
    Morgan K, Scobie G, Marsters P, Kalsheker NA (1997) Mutation in an α1-antitrypsin enhancer results in an interleukin-6 deficient acute-phase response due to loss of co-ope-rativity between transcription factors. BBA 1362: 67–76PubMedGoogle Scholar
  102. 102.
    Cox DW, Billingsley GD, Mansfield T (1987) DNA restriction-site polymorphisms associated with the fli-antitrypsin gene. Am J Hum Genet 41: 891–906PubMedGoogle Scholar
  103. 103.
    Lindmark BE, Arborelius M, Erikksson S (1990) Pulmonary deficiency in middle-aged women with heterozygous deficiency of the serine proteinase inhibitor α1-antichymotryp-sin. Am Rev Respir Dis 141: 884–888PubMedGoogle Scholar
  104. 104.
    Poller W, Faber J-P, Weidinger S, Tief K, Scholz S, Fischer M, Olek K, Kirkgesser M, Heidt-mann HH (1993) A Leucine-to-Proline substitution causes a defective α1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 17: 740–743PubMedGoogle Scholar
  105. 105.
    Janoff A (1985) Elastases and emphysema. Current assessment of the protease-antipro-tease hypothesis. Am Rev Respir Dis 132: 417–433PubMedGoogle Scholar
  106. 106.
    Dickson I, Apler CA (1974) Changes in serum proteinase levels following bons surgery. Clin ChemActa 54: 381Google Scholar
  107. 107.
    Mornex JF, Chytil-Weir A, Martinet Y, Courtney M, LeCocq JP, Crystal RG (1986) Expression of the α1-antitrypsin gene in mononuclear phagocytes of normal and α1-antitrypsin deficient individuals. J Clin Invest 11: 1952–1961Google Scholar
  108. 108.
    Perlmutter DH, Cole FS, Kilbridge P, Rossing TH, Cotten HR (1985) Expression of the α1-proteinase inhibitor gene in human monocytes and macrophages. Proc Natl Acad Sci USA 82: 795–799PubMedGoogle Scholar
  109. 109.
    Lodish HF, Kong N, Snider M, Strous GJAM (1983) Hepatoma secretory proteins migrate from rough endoplasmic reticulum to Golgi at characteristic rates. Nature (Lond) 304: 80–83Google Scholar
  110. 110.
    Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC (1986) Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 232: 347–352Google Scholar
  111. 111.
    Barbey-Morel C, Pierce JA, Campbell EJ, Perlmutter DH (1987) Lipopolysaccharide modulates the expression of α1-proteinase inhibitor and other serine proteinase inhibitors in human monocytes and macrophages. J Exp Med 166: 1041–1054PubMedGoogle Scholar
  112. 112.
    Lal EC, Kao FT, Law ML, Woo SLC (1983) Assignment of the α1-antitrypsin gene and a sequence-related gene to human chromosome 14 by molecular hybridisation. Am J Hum Genet 35: 385–392Google Scholar
  113. 113.
    Long GL, Chandra T, Woo SLC, Davie EW, Kurachi K (1984) Complete sequence of the cDNA for human α1-antitrypsin and the gene for the S variant. Biochemistry 23: 4828–4837PubMedGoogle Scholar
  114. 114.
    Perlino E, Cortese R, Ciliberto G (1987) The human α1-antitrypsin gene is transcribed from two different promoters in macrophages and hepatocytes. EMBO J 6: 2767–2771PubMedGoogle Scholar
  115. 115.
    Hafeez W, Ciliberto G, Perlmutter DH (1992) Constitutive and modulated expression of the human α1-antitrypsin gene: different transcriptional initiation sites used in three different cell types. J Clin Invest 89: 1214–1222PubMedGoogle Scholar
  116. 116.
    Kalsheker N, Swanson T (1990) Exclusion of an exon in monocyte α1-antitrypsin mRNA after stimulation of U937 cells by interleukin-6. Biochem Biophys Res Commun 172: 1116–1121PubMedGoogle Scholar
  117. 117.
    Shen R-F, Li Y, Sifers RN, Wang H, Hardick C, Tsai SY, Woo SLC (1987) Tissue-specific expression of the human α1-antitrypsin gene is controlled by multiple cis-regulatory elements. Nucleic Acid Res 15: 8399–8415PubMedGoogle Scholar
  118. 118.
    Ciliberto G, Dente L, Cortese R (1985) Cell-specific expression of a transfected human α1-antitrypsin gene. Cell 41: 531–540PubMedGoogle Scholar
  119. 119.
    De Simone V, Ciliberto G, Hardon E, Paonessa G, Palla F, Lundberg L, Cortese P (1987) Cis and transacting elements responsible for the cell-specific expression of the human α1-antitrypsin gene. EMBO J 6: 2759–2766PubMedGoogle Scholar
  120. 120.
    Hardon EM, Fain M, Poonessa G, Cortese R (1987) Two distinct factors interact with the promoter regions of several liver-specific genes. EMBO J 7: 1711–1719Google Scholar
  121. 121.
    De Simone, Cortese R (1989) A negative regulatory element in the promoter of the human α1-antitrypsin gene. Nucleic Acid Res 17: 9407–9415PubMedGoogle Scholar
  122. 122.
    Wu Y, Foreman RC (1991) The molecular genetics of α1-antitrypsin deficiency. Bioessays 13: 163–169PubMedGoogle Scholar
  123. 123.
    Gstaiger M, Knoepfel L, Georgiev O, Schaffner W, Hovens CM (1995) A β-cell co-activator of octamer-binding transcription factors. Nature 373: 360–362PubMedGoogle Scholar
  124. 124.
    Schubart DB, Sauter P, Massa S, Friedl EM, Schwarzenbach H, Matthias P (1986) Gene structure and characterisation of the murine homologue of the cell-specific transcriptional co-activator OBF-1. Nucleic Acid Res 24: 1913–1920Google Scholar
  125. 125.
    Ruvkin G, Finney M (1991) Regulation of transcription and cell identity by POU domain proteins. Cell 64: 475–478Google Scholar
  126. 126.
    Liang Y, Carr LG (1996) Identification of an octamer-1 transcription factor binding site in the promoter of the mouse m-opioid receptor gene. J Neurochem 67: 1352–1359PubMedGoogle Scholar
  127. 127.
    Sterling K, Weaver J, Ho K-L, Xu LC, Bresruck E (1993) Rat CYP 1A1 negative regulatory element: biological activity and interaction with a protein from liver and hepatoma cells. Mol Pharmacol 44: 560–568PubMedGoogle Scholar
  128. 128.
    Lin HK, Penning TM (1995) Cloning, sequencing and functional analysis of the 5′ flanking region of the rat 3α-hydroxysteroid/dihydrodiol dehydrogenase gene. Cancer Res 55: 4105–4113PubMedGoogle Scholar
  129. 129.
    Clark AR, Wilson ME, Leibiger I, Scott V, Docherty K (1995) A silencer and an adjacent postive element interact to modulate the activity of the human insulin promoter. EurJ Biochem 232: 627–632Google Scholar
  130. 130.
    Ullman KS, Northrop JP, Admon A, Crabtree GR (1993) Jun family members are controlled by a calcium-regulated cyclosporin A-sensitive signalling pathway in activated T lymphocytes. Genes Devell: 188–196Google Scholar
  131. 131.
    Strubin M, Newell JW, Matthias P (1995) OBF-1, a novel B cell-specific co-activator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins. Cell 80: 497–506PubMedGoogle Scholar
  132. 132.
    Nakshatri H, Nakshatri P, Currie RA (1995) Interaction of Oct-1 withTFIIB: implications for a novel response elicited through the proximal octamer site of the lipoprotein lipase promoter. J Biol Chem 270: 19613–19623PubMedGoogle Scholar
  133. 133.
    Saatcioglu F, Deng T, Karin M (1993) A novel cis element mediating ligand-independent activation by c-ErbA: implications for hormonal regulation. Cell 75: 1095–1105PubMedGoogle Scholar
  134. 134.
    Pearce D, Yamamoto KR (1993) Mineralocorticol and glucocorticoid receptor activities distinguished by non-receptor factors at a composite response element. Science 259: 1161–1165PubMedGoogle Scholar
  135. 135.
    Ray A, Goa X, Ray BK (1995) Role of a distal enhancer containing a functional NFarB binding site in lipopolysacchardie-induced expression of a novel α1-antitrypsin gene. J Biol Chem 270: 29201–29208PubMedGoogle Scholar
  136. 136.
    Das S, Potter H (1995) Expression of the Alzheimer amyloid-promoting factor antichy-motrypsin is induced in human astrocytes by IL-1. Neuron 14: 447–456PubMedGoogle Scholar
  137. 137.
    Cichy J, Potempa J, Chawla RK, Travis J (1995) Regulation of α1-antichymotrypsin synthesis in cells of epithelial origin. FEBS Lett 359: 262–266PubMedGoogle Scholar
  138. 138.
    Gaillard I, Clauser E, Correl P (1989) Structure of the human angiotensinogen gene. DNA 8: 87–99PubMedGoogle Scholar
  139. 139.
    Gauldie JC, Richards C, Northemann W, Fey G, Baumann H (1989) IFN-β2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes. Ann NY Acad Sci 557: 46PubMedGoogle Scholar
  140. 140.
    Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J (1992) Recombinant oncosta-tin M stimulates the production of acute-phase proteins in Hep G2 and rat primary hepatocytes in vitro. J Immunol 148: 1731–1736PubMedGoogle Scholar
  141. 141.
    Baumann H, Schendel P (1991) Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. J Biol Chem 266: 1Google Scholar
  142. 142.
    Baumann H, Gauldie J (1990) Regulation of hepatic acute-phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 7: 147–160PubMedGoogle Scholar
  143. 143.
    Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute-phase response. Bio-chem J 265: 621–636Google Scholar
  144. 144.
    Brasier AR, Ron D, Tate JE, Habener JF (1990) A family of constitutive C/EBP-like DNA binding proteins attenuate the IL-1 a induced NFкB mediated transactivation of the angiotensinogen gene acute-phase response element. EMBO J 9: 3933–3944PubMedGoogle Scholar
  145. 145.
    Adcock IM, Brown CR, Gelder CM, Shiraski H, Peters MJ, Barnes PJ (1995) Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol 268: C331–C338PubMedGoogle Scholar
  146. 146.
    Barnes PJ, Larin M (1997) Nuclear factor-кB-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066–1071PubMedGoogle Scholar
  147. 147.
    Fujita T, Nolan GP, Ghosh S, Baltimore D (1992) Independent modes of transcriptional activation by the p50 and p65 sub-units of NFкB. Genes Devel 6: 775–787PubMedGoogle Scholar
  148. 148.
    Schmitz ML, Baeuerle PA (1991) The p65 sub-unit is responsible for the strong transcription activating potential of NFкB. EMBO J 10: 3805–3817PubMedGoogle Scholar
  149. 149.
    Roff M, Thompson J, Rodriquez MS, Jacques J-M, Baleux F, Arenzana-Seisdedos F, Hay RT (1996) Role of IкBαubiquitination in signal-induced activation of NFкB in vivo. J Biol Chem 271: 7844–7850PubMedGoogle Scholar
  150. 150.
    Baldwin AS Jr (1996) The NFкB and IкB proteins: new discoveries and insights. Annu Rev Immunol 14: 649–683PubMedGoogle Scholar
  151. 151.
    DiDonato J, Merairio F, Rosette, Wuli J, Suyang H, Ghosh S, Karin M (1996) Mapping of the inducible IкB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 16: 1295–1304PubMedGoogle Scholar
  152. 152.
    Chen ZI, Parent L, Maniatis T (1996) Site-specific phosphorylation of IкBa by a novel ubiquitination-dependent protein kinase activity. Cell 84: 853–862PubMedGoogle Scholar
  153. 153.
    Arenzana-Seisdedos F, Thompson J, Rodriquez MS, Bachelerie F, Thomas D, Hay RT (1995) Inducible nuclear expression of newly synthesised IкBα negatively DNA-binding and transcriptional activities of NFKB. Mol Cell Biol 15: 2689–2696PubMedGoogle Scholar
  154. 154.
    Hirano T, Akiva S, Taga T, Kishimoto T (1990) Biological and clinical aspects of interleukin-6. Immunol Today 11: 443–449PubMedGoogle Scholar
  155. 155.
    Akira S, Isshiki H, Sugita T, Tambe O, Kinoshita S, Nishio Y, Nakajima T, Hirano T, Kishimoto T (1990) A nuclear factor for IL-6 expression (NF-IL-6) is a member of a C/EBP family. EMBO J 9: 1897–1906PubMedGoogle Scholar
  156. 156.
    Isshiki H, Akira S, Sugita T, Nishio Y, Hashimoto S, Pawlowski T, Suematus S, Kishimo-to T (1991) Recipricol expression of NF-IL-6 and C/EBP in hepatocytes: possible involvement of NF-IL-6 in acute phase protein gene expression. New Biol 3: 63–70PubMedGoogle Scholar
  157. 157.
    Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T, Akira S (1993) Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL-6. Proc Natl Acad Sci USA 90: 2207–2211PubMedGoogle Scholar
  158. 158.
    Ramji DP, Vitelli A, Tronche F, Cortese R, Ciliberto G (1993) The two isoforms IL-6DBP/NF-IL-6 and C/EBPy/NFIL-6β, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic Acid Res 21: 289–294PubMedGoogle Scholar
  159. 159.
    Wegemka UM, Luttichen C, Bischman J, Yvan J, Lottspeich F, Muller-Esterl W, Schindler C, Roeb E, Heinrich PC, Horn F (1994) The interleukin-6 activated acute-phase response factor is antigenically and functionally related to members of the signal transduced and activator (STAT) family. Mol Cell Biol 14: 3186–3196Google Scholar
  160. 160.
    Wilson DR, Juan TS-C, Wilde MD, Fey GH, Darlington GJ (1990) A 58-base-pair region of the human C3 gene confers synergistic inducibility by interleukin-1 and interleukin-6. Mol Cell Biol 10: 6181–6191PubMedGoogle Scholar
  161. 161.
    Hocke GM, Barry D, Fey GH (1992) Synergistic action of interleukin-6 and glucocorti-coids is mediated by the interleukin-6 response element of the rat α2 macroglobulin gene. Mol Cell Biol 12: 2282–2294PubMedGoogle Scholar
  162. 162.
    Kordula T, Bugno M, Goldstein J, Travis J (1995) Activation of signal transducer and activator of transcription-3 (STAT-3) expression by interferon y and interleukin-6 in hepa-toma cells. Biochem Biophys Res Commun 216: 999–1005PubMedGoogle Scholar
  163. 163.
    Kishimoto T, Akira S, Narazaki M, Taga T (1995) Interleukin-6 family of cytokines and gp 130. Blood 86: 1243–1254PubMedGoogle Scholar
  164. 164.
    Wen Z, Zhong Z, Darnell JE Jr (1995) Maximal activation of transcription by Stat 1 and Stat 3 requires both tyrosine and serine phosphorylation. Cell 82: 241–250PubMedGoogle Scholar
  165. 165.
    Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P (1993) The role of NFJCB and NF-IL-6 transactivating factors in the synergistic activation of serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 268: 25624–25631PubMedGoogle Scholar

Copyright information

© Springer Basel AG 1999

Authors and Affiliations

  • Jean-Michel Sallenave
    • 1
  • Kevin Morgan
    • 2
  • Jack Gauldie
    • 3
  • Noor Kalsheker
    • 2
  1. 1.Rayne Laboratory, Department of MedicineEdinburgh Medical SchoolEdinburghScotland, UK
  2. 2.Division of Clinical Chemistry, School of Clinical Laboratory Sciences, Faculty of MedicineQueen Medical CentreNottinghamUK
  3. 3.Department of PathologyMcMaster UniversityHamilton, OntarioCanada

Personalised recommendations